First Wave BioPharma Inc expected to post a loss of $2.43 a share - Earnings Preview

GridAI Technologies

11/05/2024 24:34

* First Wave BioPharma Inc  FWBI.OQ   FWBI.O  is expected
to show
no change in quarterly revenue when it reports  results on May
12 (estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for First Wave BioPharma Inc
is
for a loss of $2.43 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 13.5%
in the last three months. ​
    * Wall Street's median 12-month price target for First Wave
BioPharma Inc is $36.00​, above​ its last closing price
of $2.85. ​​​

This summary was machine generated May 10 at 23:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)